IL89276A - A preparation containing human relaxin - Google Patents

A preparation containing human relaxin

Info

Publication number
IL89276A
IL89276A IL8927689A IL8927689A IL89276A IL 89276 A IL89276 A IL 89276A IL 8927689 A IL8927689 A IL 8927689A IL 8927689 A IL8927689 A IL 8927689A IL 89276 A IL89276 A IL 89276A
Authority
IL
Israel
Prior art keywords
relaxin
composition
buffer
formulation
gel
Prior art date
Application number
IL8927689A
Other languages
English (en)
Hebrew (he)
Other versions
IL89276A0 (en
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to IL108658A priority Critical patent/IL108658A/en
Publication of IL89276A0 publication Critical patent/IL89276A0/xx
Publication of IL89276A publication Critical patent/IL89276A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Electrotherapy Devices (AREA)
  • Materials For Medical Uses (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
IL8927689A 1988-02-26 1989-02-14 A preparation containing human relaxin IL89276A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL108658A IL108658A (en) 1988-02-26 1989-02-14 Human relaxin pharmaceutical gel compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16079788A 1988-02-26 1988-02-26
US30377989A 1989-01-27 1989-01-27

Publications (2)

Publication Number Publication Date
IL89276A0 IL89276A0 (en) 1989-09-10
IL89276A true IL89276A (en) 1994-06-24

Family

ID=26857232

Family Applications (1)

Application Number Title Priority Date Filing Date
IL8927689A IL89276A (en) 1988-02-26 1989-02-14 A preparation containing human relaxin

Country Status (14)

Country Link
US (2) US5451572A (pt)
EP (1) EP0407401B1 (pt)
JP (1) JP2815649B2 (pt)
CN (1) CN1052655C (pt)
AT (1) ATE88352T1 (pt)
AU (1) AU626840B2 (pt)
CA (1) CA1336403C (pt)
DE (1) DE68906153T2 (pt)
ES (1) ES2013394A6 (pt)
IE (1) IE63208B1 (pt)
IL (1) IL89276A (pt)
NZ (1) NZ228012A (pt)
PT (1) PT89835B (pt)
WO (1) WO1989007945A1 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
US5478807A (en) * 1991-08-19 1995-12-26 Genentech, Inc. Use of relaxin in the treatment of bradycardia
JPH07508341A (ja) * 1991-10-28 1995-09-14 ボード・オヴ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム 生物サンプルおよび体液中の正常細胞と悪性腫瘍細胞とにおける分化マーカーの検出方法
US5192743A (en) * 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
US5830848A (en) * 1992-10-09 1998-11-03 The Regents Of The University Of California Method and agents for inducement of endogenous nitric oxide synthase for control and management of labor during pregnancy
KR100215739B1 (ko) * 1994-10-13 1999-08-16 오쿠다 기요아키 가역성열겔화 수용성 의약 조성물을 함유하는 동결건조 제제
US5811395A (en) * 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
CA2229479C (en) * 1995-08-15 2010-03-30 Connective Therapeutics, Inc. Method of promoting angiogenesis
US5612051A (en) * 1995-11-17 1997-03-18 Yue; Samuel K. Method of treating involuntary muscle dysfunction with relaxin hormone
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US5994148A (en) * 1997-06-23 1999-11-30 The Regents Of University Of California Method of predicting and enhancing success of IVF/ET pregnancy
US6251863B1 (en) 1998-09-08 2001-06-26 Samuel K. Yue Method of preventing and treating symptoms of aging and neurodegenerative dysfunctions with relaxin
MXPA01006011A (es) * 1998-12-18 2004-04-05 Palladin Healthcare Internatio Composicion para tratamiento de quemaduras.
CA2397200C (en) * 2000-02-09 2010-11-23 Connetics Corporation Use of relaxin to treat diseases related to vasoconstriction
US20050032683A1 (en) * 2000-10-04 2005-02-10 Amento Edward P. Methods of modulating apoptosis by administration of relaxin agonists or antagonists
EP1391209A4 (en) * 2001-05-30 2009-12-16 Chugai Pharmaceutical Co Ltd PROTEIN PREPARATION
US20100134794A1 (en) * 2004-02-05 2010-06-03 Medpro Holdings, Llc Analyzer for determining the concentration, potency and purity of pharmaceutical compounds
US7660678B2 (en) * 2004-02-05 2010-02-09 Medpro Holdings, Llc On-site method of providing analysis of potency and purity of pharmaceutical compounds
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
WO2005115435A2 (en) * 2004-04-30 2005-12-08 Bas Medical, Inc. Methods and compositions for control of fetal growth via modulation of relaxin
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
JP2008513356A (ja) * 2004-08-09 2008-05-01 アリオス バイオファーマ インク． 合成高度糖鎖付加プロテアーゼ耐性ポリペプチド変異体、それを使用する経口製剤および方法
US20060052304A1 (en) * 2004-09-02 2006-03-09 Bas Medical, Inc. Method for remodeling bone and related sutures
WO2007036946A1 (en) * 2005-09-28 2007-04-05 Padma Venkitachalam Devarajan Compositions for enhanced absorption of biologically active agents
US20100041603A1 (en) * 2008-05-16 2010-02-18 Corthera, Inc. Method of Promoting Wound Healing
US20110166070A1 (en) * 2008-05-16 2011-07-07 Stewart Dennis R Method of preventing premature delivery
US20100234827A1 (en) * 2009-03-13 2010-09-16 Sigg Daniel C Method of treating heart failure
AU2011224341B2 (en) * 2010-03-10 2014-07-10 The University Of Florida Research Foundation, Inc. Modulating aquaporins with relaxin
WO2012024452A2 (en) 2010-08-17 2012-02-23 Ambrx, Inc. Modified relaxin polypeptides and their uses
CN102133200B (zh) * 2011-03-16 2012-07-25 济南环肽医药科技有限公司 一种人类松弛素-2 Relaxin的注射用冻干粉制剂
US9393288B2 (en) 2012-05-29 2016-07-19 The University Of Vermont And State Agricultural College Methods of treating diseases associated with PPARγ
CN103768584A (zh) * 2014-02-10 2014-05-07 济南环肽医药科技有限公司 一种松弛肽注射液
CN104922661B (zh) * 2014-03-20 2018-08-24 深圳翰宇药业股份有限公司 一种含有serelaxin的药物组合物及其制备方法
WO2016059593A1 (en) * 2014-10-16 2016-04-21 Piramal Enterprises Limited Stable injectable composition of protein drugs and process for its preparation
CN107007822A (zh) * 2016-01-27 2017-08-04 江苏恒瑞医药股份有限公司 一种含有重组人松弛素‑2类似物的药物组合物及其制备方法
AU2018219283B2 (en) 2017-02-08 2022-05-19 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
MX2019011603A (es) * 2017-03-26 2021-08-16 Robyn Vivi Stafford Metodo de tratamiento de las condiciones de la piel de los parpados.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2964448A (en) * 1959-01-27 1960-12-13 Anschel Joachim Relaxin composition and process for preparing same
US3003117A (en) * 1959-09-29 1961-10-03 Gen Frecision Inc Coincident frequency tracker
US3962416A (en) * 1971-01-25 1976-06-08 Sol Katzen Preserved nutrients and products
EP0018609B1 (de) * 1979-04-30 1983-09-21 Hoechst Aktiengesellschaft Gegen Denaturierung beständige, wässrige Protein-Lösungen, Verfahren zu ihrer Herstellung und ihre Verwendung
US4267101A (en) * 1980-02-01 1981-05-12 Serono Laboratories Inc. Process for obtaining human relaxin from fetal membranes
EP0080879B1 (en) * 1981-11-28 1986-10-01 Sunstar Kabushiki Kaisha Pharmaceutical composition containing interferon in stable state
ATE78042T1 (de) * 1982-08-12 1992-07-15 Florey Howard Inst Analoge des humanen relaxins.
DE3236267A1 (de) * 1982-09-30 1984-04-05 Serono Pharmazeutische Präparate GmbH, 7800 Freiburg Verfahren zur herstellung von relaxin und verfahren zur hochreinigung von relaxin
DE3236264A1 (de) * 1982-09-30 1984-04-05 Serono Pharmazeutische Präparate GmbH, 7800 Freiburg Verfahren zur gewinnung von relaxin
NZ206534A (en) * 1982-12-13 1988-05-30 Florey Howard Inst Molecular cloning and characterisation of gene sequence coding for human relaxin
CH661662A5 (en) * 1984-04-16 1987-08-14 Georg L Prof Dr Floersheim Product for the treatment of the skin and of the connective tissue
US4605555A (en) * 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
US4806343A (en) * 1986-03-13 1989-02-21 University Of Southwestern Louisiana Cryogenic protectant for proteins
AU612594B2 (en) * 1986-09-12 1991-07-18 Genentech Inc. Human prorelaxin
US4717717A (en) * 1986-11-05 1988-01-05 Ethicon, Inc. Stabilized compositions containing epidermal growth factor

Also Published As

Publication number Publication date
EP0407401B1 (en) 1993-04-21
IL89276A0 (en) 1989-09-10
CN1052655C (zh) 2000-05-24
AU3183389A (en) 1989-09-22
ES2013394A6 (es) 1990-05-01
PT89835A (pt) 1989-10-04
US5451572A (en) 1995-09-19
US5945402A (en) 1999-08-31
EP0407401A1 (en) 1991-01-16
PT89835B (pt) 1994-01-31
ATE88352T1 (de) 1993-05-15
DE68906153T2 (de) 1993-10-28
DE68906153D1 (de) 1993-05-27
IE63208B1 (en) 1995-04-05
JP2815649B2 (ja) 1998-10-27
IE890452L (en) 1989-08-26
CA1336403C (en) 1995-07-25
CN1035619A (zh) 1989-09-20
WO1989007945A1 (en) 1989-09-08
NZ228012A (en) 1991-07-26
AU626840B2 (en) 1992-08-13
JPH03502794A (ja) 1991-06-27

Similar Documents

Publication Publication Date Title
CA1336403C (en) Human relaxin formulation
EP1928413B1 (en) Hfsh aqueous formulation
KR101662631B1 (ko) Ｆｓｈ의 액체 포뮬레이션
JPH04217630A (ja) 安定化されたゴナドトロピンを含有する調製品
CA2348167C (en) Pharmaceutical administration form for peptides, process for its preparation, and use
KR101105486B1 (ko) Ｆｓｈ 및 ｌｈ과 비이온성 계면활성제의 액상 약제학적 제제
KR101024511B1 (ko) 올리고펩티드 및 에테르화된 시클로덱스트린을 포함하는액상 제제
IL172353A (en) Dry frozen fsh / lh formulations and their preparation
KR100245534B1 (ko) 피브릴화된 칼시토닌을 포함하는 약제학적 조성물, 이의 제조방법 및 칼시토닌 피브릴의 분산액
IL108658A (en) Human relaxin pharmaceutical gel compositions
JP3822383B2 (ja) 可溶性トロンボモジュリン含有組成物
US20090029911A1 (en) Liquid Human Growth Hormone Formulation Containing Polyethylene Glycol
WO2007034509A2 (en) Recombinant granulocyte-colony stimulating factor formulation and process
JP2005060377A (ja) インターロイキン−１１含有凍結乾燥製剤

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed